By Dr. Nicolas Cloarec and Dr. Marie-Magdelaine Coudé
Lung cancer is a highly heterogeneous disease at the genomic level, with numerous alterations that can lead to the use of targeted therapies. This makes molecular biology testing essential in nearly all cases of patient management.
Some tests are reimbursed, others are still listed under RIHN (Rare and Innovative Health Needs), and they range from targeted to comprehensive approaches. It is therefore crucial to understand their benefits, drawbacks, and limitations in order to use them in the most appropriate sequence for optimal patient care.
We invite you to join us for a comprehensive review of these tests, supported by notable clinical case studies.
